Evidence map›Paper›PMID 31881168›Full record

Observational studyBosnian journal of basic medical sciences2020

Serum patterns of mir-23a and mir-181b in irritable bowel syndrome and colorectal cancer - A pilot study.

Alexandra Chira, Mihai-Stefan Muresan, Cornelia Braicu, Liviuta Budisan, Lajos Raduly, Romeo Ioan Chira, Dan Lucian Dumitrascu, Ioana Berindan-Neagoe

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Bosnian journal of basic medical sciences, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. MicroRNAs in Inflammatory Bowel Disease and Its Complications.International journal of molecular sciences · 2022
    Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Alexandra ChiraDepartment of Internal Medicine, 2nd Medical Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.
Mihai-Stefan MuresanInstitute of Urology and Kidney Transplant Cluj-Napoca, Cluj-Napoca, Romania; The Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania.
Cornelia BraicuResearch Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Liviuta BudisanResearch Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Lajos RadulyResearch Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania.
Romeo Ioan ChiraDepartment of Internal Medicine, Division Gastroenterology, 1st Medical Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.
Dan Lucian DumitrascuDepartment of Internal Medicine, 2nd Medical Clinic, "Iuliu Hatieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.
Ioana Berindan-NeagoeResearch Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hatieganu" University of Medicine and Pharmacy, Cluj-Napoca, Romania; MEDFUTURE - Research Center for Advanced Medicine, University of Medicine and Pharmacy Iuliu-Hatieganu, Cluj-Napoca, Romania; Department of Functional Genomics and Experimental Pathology, The Oncology Institute "Prof. Dr. Ion Chiricuta", Cluj-Napoca, Romania.
Iuliu Hațieganu University of Medicine and Pharmacy · ROInstitute of Oncology Prof. Dr. Ion Chiricuta · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Emerging evidence demonstrates that microRNAs (miRNAs) could serve as reliable biomarkers of inflammation and oncogenesis. The aim of this study was to determine whether miR-23a and miR-181b were suitable as biomarkers of irritable bowel syndrome (IBS) and colorectal cancer (CRC). Forty patients with IBS (29 females, 11 males), 33 with CRC (14 females, 19 males), and 33 healthy controls (17 females, 16 males) were prospectively included. Serum levels of miRNAs were evaluated by quantitative real-time PCR. The serum levels of miR-23a and miR-181b were significantly higher in the IBS group (p = 0.0009 and 0.004, respectively) and CRC group (p = 0.002 and 0.029, respectively) than in the control group. Serum levels of miR-23a and miR-181b were upregulated in CRC vs. IBS, but the differences did not reach statistical significance (p = 0.169 and 0.179, respectively). The miRNet and Reactome databases identified phosphatase and tensin homolog as a major common pathway, indicating inflammation as a central hallmark. Although miRNAs could serve as reliable biomarkers in clinical practice, future studies are needed to establish appropriate cut-off limits.

Indexed as

AdultAgedBiomarkersCase-Control StudiesColorectal NeoplasmsFemaleHumansIrritable Bowel SyndromeMaleMicroRNAsMiddle AgedPilot ProjectsProspective StudiesSensitivity and SpecificityBiomarkersMicroRNAsMIrn181 microRNA, humanMIRN23a microRNA, human

Identifiers

PMID31881168
PMCPMC7202192
OpenAlexW2991796620

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.